AXSM Q2 2024 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$87M+86.7% YoY

Gross Profit

$79M90.8% margin

Operating Income

-$78M-89.5% margin

Net Income

-$79M-91.0% margin

EPS (Diluted)

$-1.67

QoQ Revenue Growth

+16.2%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$548M

Total Liabilities

$445M

Stockholders' Equity

$103M

Cash & Equivalents

$316M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$87M	$47M	+86.7%
Gross Profit	$79M	$42M	+87.9%
Operating Income	-$78M	-$65M	-20.0%
Net Income	-$79M	-$67M	-18.1%

Revenue Segments

Product

$87M99%

Royalty

$646,0001%

Geographic Segments

UNITED STATES

$85M99%

Non-US

$1M1%